The Latest
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Cancer drug startup Lirum Pharmaceuticals set terms for what could be the 11th IPO so far this year. But it would also be one of the smallest, with about $25 million in anticipated proceeds.
Updated April 19, 2024 -
shutterstock.com/ALDECA studio
Sponsored by PhreesiaHow can pharma speed time to treatment? Digital tools can help
Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.
-
Scott Olson via Getty Images
Lilly to buy injectable drug plant in manufacturing ramp-up
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
-
selvanegra via Getty Images
Eisai hunts for next Alzheimer’s drug with new research pact
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
-
Courtesy of Ipsen
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
-
Courtesy of Teva Pharmaceutical
Alvotech deal could heighten biosimilar pressure on Humira
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is on the upswing. Track the latest deals here.
Vertex’s proposed buyout of Alpine Immune Sciences is the largest biotech acquisition to be announced so far this year.
Updated April 10, 2024 -
Courtesy of Roche
Roche wins FDA OK for Alecensa in early lung cancer
Alecensa is the first targeted drug available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.
-
Douglas Cliff via Getty Images
Emerging biotechMetsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.
-
Courtesy of Vertex Pharmaceuticals
Vertex begins bid for US approval of non-opioid painkiller
The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.
-
Brad Barket via Getty Images
23andMe CEO plans to take company private
Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.
-
Scott Olson via Getty Images
Obesity drugsLilly obesity drug shows benefit in sleep disorder study, pointing to new use
Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.
-
noparrit via Getty Images
Sage’s cognition drug fails in Parkinson’s study
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
-
Courtesy of Teva Pharmaceutical
Stelara biosimilar from Alvotech, Teva approved by FDA
The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.
-
Chris McGrath via Getty Images
Ukraine was pharma’s clinical trial ‘darling.’ As war drags on, will the industry return?
While some new drug studies are getting underway, activity is still far below bustling pre-war levels.
-
Permission granted by Canaan
Canaan hires Pfizer executive, reels in $100M for biotech investing
The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.
-
Mario Tama via Getty Images
J&J sees mixed performance from new multiple myeloma drugs
Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."
-
Eoneren via Getty Images
Intra-Cellular builds case for depression drug with late-stage trial win
Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.
-
Dr_Microbe via Getty Images
Cullinan changes name, pivots to autoimmune disease
The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.
-
Regeneron commits $500M to new venture capital fund
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.
-
Permission granted by Neumora Therapeutics
Neumora’s schizophrenia drug hit with clinical hold
Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.
-
iStock via Getty Images
Roche reports survival data for new dual-acting lymphoma drug
The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.
-
Image courtesy of Ultragenyx.
Ultragenyx says Angelman therapy is working, but safety questions remain
Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.
-
Spencer Platt via Getty Images
Biotech IPOs bounced back in first quarter, but backlog remains
Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.
-
Mario Tama via Getty Images
European regulator concludes no suicide link to obesity drugs
The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.
-
Nemes Laszlo via Getty Images
Roche, Adaptimmune part ways on cell therapy research
The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.
